

Supporting Information
for DOI: 10.1055/a-2602-6763

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG, Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Supporting Information

Pyrimidine Carboxylic Acids Linked through 1, 4, 5- Trisubstituted 1, 2, 3-Triazoles:

Synthesis and RNase A Inhibition Studies

Kaustav Chakraborty, Swagata Dasgupta*, Tanmaya Pathak*

Department of Chemistry, Indian Institute of Technology Kharagpur,

Kharagpur 721302, India

Experimental Section for the Synthesis of Compounds	2-6
NMR spectra of the synthesized compounds	7-22
Figure S1: Mechanism for the transphosphorylation and hydrolysis reactions catalyzed by enzyme RNase A.	23
Figure S2: Transition state during transphosphorylation of UpA by RNase A	23
Figure S3: Reported nucleoside based Ribonuclease A inhibitors	24
Figure S4: Lineweaver-Burk plots for inhibition of RNase A	25
Figure S5: Docked poses of inhibitors with RNase A	26
Table S1: Distances of polar contacts between inhibitors and amino acid residues of RNase A (1FS3)	27

Experimental Section for the Synthesis of Compounds

General methods

All reagents and fine chemicals were purchased from commercial suppliers and were used without further purification. Column chromatographic separations were done using silica gel (230-400 mesh). Solvents were dried and distilled following standard procedures. TLC was carried out on precoated plates (Merck silica gel 60, f_{254}) and the spots were visualized with UV light or by charring the plates dipped in 5% H_2SO_4 -MeOH solution or 5% H_2SO_4 /vanillin/EtOH solution. ^1H and ^{13}C NMR for the compounds were recorded at 200/400/600 and 50/100/150 MHz respectively using a Bruker NMR instrument unless stated otherwise. Chemical shifts are reported in parts per million (ppm, δ scale). DEPT experiments have been carried out to identify the methylene carbons. Melting points were determined in open-end capillary tubes. Bovine pancreatic RNase A, RNA (*Torulautilis*) and 2', 3'-cCMP were purchased from commercial suppliers. UV-Vis measurements were made using a UV-Vis spectrophotometer (Shimadzu 2450). Concentrations of the solutions were estimated spectrophotometrically using the following data: $\epsilon_{278.5} = 9800 \text{ M}^{-1}\text{cm}^{-1}$ (RNase A)⁵⁵ and $\epsilon_{268} = 8500 \text{ M}^{-1}\text{cm}^{-1}$ (2', 3'-cCMP)¹⁷. Mass spectroscopy data were obtained from Xevo G2QT mass spectrometer.

General procedure for the triazolylation reaction

To a well-stirred solution of the azide (1 mmol) in CCl_4 (5 ml) was added DMAD (1.5 mmol). The resulting mixture was allowed to reflux for 24h. The solvent was evaporated under reduced pressure, and the residue was purified by column chromatography under reduced pressure (EtOAc-pet ether) to obtain pure product.

General procedure for ester hydrolysis

To a well stirred solution of the compound (1 mmol) in methanol (5 ml) at 0 °C, was added 1 (N) NaOH solution (2 ml) dropwise. The resulting solution was allowed to warm back to room temperature and stirred for 2h. After evaporation of methanol under reduced pressure, the resulting residue was dissolved in water (10 ml) and neutralized with acidic amberlyte. The resulting mixture was filtered, and the filtrate was evaporated under reduced pressure to obtain pure product.

Compound 4

Compound **4** (0.42 g, 75%) was synthesized from compound **3** (0.6 g, 1.46 mmol) following the general procedure of ester hydrolysis. White solid. ^1H NMR (600 MHz, DMSO- d_6): δ 1.80 (s, 3H), 2.51-2.63 (m, 1H), 2.69-2.73 (m, 1H), 3.69-3.77 (m, 2H), 4.27-4.28 (m, 1H), 6.07-6.08 (m, 1H), 6.53-6.55 (m, 1H), 7.94 (s, 1H).

(ref: Häbic, D.; Barth, W.; Rösner, M. *Heterocycles* **1989**, 29, 2083)

Compound 6

Compound **6** (0.50 g, 87%) was obtained from compound **5** (0.42 g, 1.10 mmol) using the general procedure of triazolylolation. [Eluent: 35-45% EtOAc in pet ether]. Colourless gum. ^1H NMR (200 MHz, CDCl_3): δ 0.04 (s, 3H), 0.08 (s, 3H), 0.84 (s, 9H), 1.81 (s, 3H), 2.00-2.28 (m, 2H), 3.83 (s, 3H), 3.90 (s, 3H), 4.02-4.09 (m, 1H), 4.27-4.36 (m, 1H), 4.76-5.01 (m, 2H), 6.07 (t, $J = 6.4$ Hz, 1H), 6.60 (s, 1H), 9.80 (s, 1H). ^{13}C NMR (50 MHz, CDCl_3): δ -4.7, -4.6, 12.3, 17.9, 25.6, 39.4 (CH_2), 49.9 (CH_2), 52.8, 53.4, 71.5, 83.7, 85.4, 111.5, 131.7, 135.7, 139.5, 150.4, 159.1, 160.2, 164.0. HRMS (ESI $^+$): m/z calcd for $\text{C}_{22}\text{H}_{34}\text{N}_5\text{O}_8\text{Si}(\text{M}+\text{H})^+$: 524.2177; found: 524.2155.

Compound 7

To a well-stirred solution of compound **6** (0.43 g, 0.82 mmol) in methanol (10 ml), was added CH_3COCl (cat). The resulting solution was allowed to stir for 2h at room temperature. The solvent was evaporated under reduced pressure and the resulting residue was purified by column chromatography over silica gel to obtain **7** (0.28 g, 83%). [Eluent: 4% MeOH in DCM]. ^1H NMR (200 MHz, DMSO- d_6): δ 1.74 (s, 1H), 2.05-2.35 (m, 2H), 3.80 (s, 3H), 3.84 (s, 3H), 3.95-4.02 (m, 1H), 4.17-4.25 (m, 1H), 4.79-4.98 (m, 2H), 5.56 (d, $J = 4.8$ Hz, 1H), 6.09 (t, $J = 6.2$ Hz, 1H), 7.13 (s, 1H), 11.29 (s, 1H).

Compound 8

Compound **8** (0.17 g, 78%) was obtained from compound **7** (0.23 g, 0.56 mmol) applying general procedure of ester hydrolysis. White solid. M.P: 196-198 °C. ^1H NMR (200 MHz, DMSO- d_6): δ 1.82 (s, 3H), 2.02-2.19 (m, 2H), 4.22-4.30 (m, 2H), 4.95-5.18 (m, 2H), 6.15 (t, $J = 7.4$ Hz, 1H), 7.55 (s, 1H), 11.30 (s, 1H). ^{13}C NMR (50 MHz, DMSO- d_6): δ 12.0, 38.0 (CH_2), 51.3 (CH_2), 71.1, 84.3 (2xC), 109.7, 132.9, 136.1, 140.6, 150.4, 159.2, 161.2, 163.7. HRMS (ESI $^+$): m/z calcd for $\text{C}_{14}\text{H}_{16}\text{N}_5\text{O}_8(\text{M}+\text{H})^+$: 382.0999; found: 382.0887.

Compound 10

Compound **9** (0.35 g, 1.13 mmol) was converted to **10** (0.41 g, 81%) using general procedure of triazolylolation. [Eluent: 50-60% EtOAc in pet ether]. Yellow solid. M.P: 115-117 °C. ¹H NMR (200 MHz, CDCl₃): δ 1.33 (s, 3H), 1.52 (s, 3H), 3.86 (s, 3H), 3.95 (s, 3H), 4.45-4.53 (m, 1H), 4.88-5.14 (m, 4H), 5.39 (s, 1H), 5.71-5.75 (m, 1H), 7.09 (d, *J* = 8.0 Hz, 1H), 9.13 (bs, 1H). ¹³C NMR (50 MHz, CDCl₃): δ 25.3, 27.1, 51.5 (CH₂), 52.8, 53.5, 81.8, 84.5, 87.3, 96.9, 102.8, 114.7, 131.3, 139.7, 144.0, 150.4, 159.1, 160.5, 163.9. HRMS (ESI⁺): *m/z* calcd for C₁₈H₂₂N₅O₉(M+H)⁺ : 452.1418; found: 452.1411.

Compound 11

1:1 TFA:DCM mixture (2 ml) was added to compound **10**(0.35 g, 0.77 mmol), and stirred at room temperature for one hour. The reaction mixture was then evaporated under reduced pressure, and purified by column chromatography over silica gel to obtain compound **11** (0.24g, 74%).[Eluent: 5-10% MeOH in DCM]. Yellow gum. ¹H NMR (200 MHz, DMSO-*d*₆): δ 3.82 (s, 3H), 3.85 (s, 3H), 3.94-4.18 (m, 3H), 4.79-5.00 (m, 2H), 5.38 (d, *J* = 6.0 Hz , 1H), 5.5 (d, *J* = 5.4 Hz, 1H), 5.57-5.62 (m, 2H), 7.48 (d, *J* = 8.2 Hz, 1H), 11.34 (s, 1H). ¹³C NMR (50 MHz, DMSO-*d*₆): δ 51.0 (CH₂), 52.5, 53.4, 70.1, 72.0, 81.0, 90.6, 101.9, 131.5, 138.6, 141.9, 150.4, 158.7, 160.0, 163.1. HRMS (ESI⁺): *m/z* calcd for C₁₅H₁₈N₅O₉(M+H)⁺ : 412.1105; found: 412.1085.

Compound 12

Compound **12** (0.11 g, 64%) was generated from compound **11**(0.18 g, 0.44 mmol) following general procedure of ester hydrolysis. White solid. M.P: 118-120 °C. ¹H NMR (600 MHz, DMSO-*d*₆): δ 3.17 (s, 1H), 4.01-4.02 (t, *J* = 4.8 Hz, 1H), 4.15-4.16 (t, *J* = 5.4 Hz, 1H), 4.19-4.21 (m, 1H), 5.62-5.63 (d, *J* = 8.4 Hz, 1H), 5.72-5.73 (d, *J* = 5.4 Hz, 1H), 7.61-7.63 (m, 2H), 11.34 (s, 1H). ¹³C NMR (50 MHz, DMSO-*d*₆): δ 51.3 (CH₂), 70.7, 72.2, 81.8, 88.6, 102.0, 132.5, 140.3, 141.2, 150.7, 159.3, 161.4, 163.1. HRMS (ESI⁺): *m/z* calcd for C₁₃H₁₄N₅O₉(M+H)⁺ : 384.0792; found: 384.0796.

Compound 14

Compound **13** (0.40 g, 0.78 mmol) was transformed to compound **14** (0.29 g, 56%) using the general procedure of triazolylolation over 48 h. [Eluent: 60-70% EtOAc in pet ether]. Colourless gum. ¹H NMR (600 MHz, CDCl₃): δ 3.45-3.47 (m, 1H), 3.61-3.63 (m, 1H), 3.87 (s, 1H), 3.97 (s, 3H), 4.74-4.77 (m, 1H), 5.04 (t, *J* = 6.0 Hz, 1H), 5.41 (d, *J* = 7.8 Hz, 1H), 5.70-5.72(m, 1H),

6.36 (d, $J = 5.4$ Hz, 1H), 7.23-7.41 (m, 15H), 7.96 (d, $J = 8.4$ Hz, 1H), 10.23 (s, 1H). ^{13}C NMR (150 MHz, CDCl_3): 52.9, 53.7, 61.6 (CH_2), 64.4, 76.1, 79.0, 85.3, 87.7, 101.4, 127.4, 128.0, 128.1, 128.6, 128.7, 131.2, 139.9, 142.0, 143.1, 150.8, 158.4, 160.2, 164.6. HRMS (ESI^+): m/z calcd for $\text{C}_{34}\text{H}_{31}\text{N}_5\text{O}_9(\text{M}+\text{H})^+$: 654.2200; found: 654.2207.

Compound 15

1:1 TFA:DCM mixture (2 ml) was added to compound **14** (0.23 g, 0.35 mmol), and stirred at room temperature for one hour. The reaction mixture was then evaporated under reduced pressure, and purified by column chromatography over silica gel to obtain compound **15** (0.11 g, 77%). [Eluent: 5-10% MeOH in DCM]. Yellow gum. ^1H NMR (600 MHz, $\text{DMSO}-d_6$): δ 3.58-3.60 (m, 1H), 3.71-3.73 (m, 1H), 3.89 (s, 3H), 3.95 (s, 3H), 4.36-4.38 (m, 1H), 4.83 (q, $J = 5.4$ Hz, 1H), 5.25 (s, 1H), 5.28-5.30 (m, 1H), 5.65-5.66 (m, 1H), 6.27 (d, $J = 5.4$ Hz, 1H), 6.31 (d, $J = 5.4$ Hz, 1H), 7.77 (d, $J = 8.4$ Hz, 1H), 11.36 (d, $J = 1.8$ Hz, 1H). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ 53.2, 54.3, 60.3 (CH_2), 66.1, 75.0, 81.2, 85.1, 101.0, 131.9, 139.3, 142.6, 150.9, 158.8, 160.5, 163.7. HRMS (ESI^+): m/z calcd for $\text{C}_{15}\text{H}_{18}\text{N}_5\text{O}_9(\text{M}+\text{H})^+$: 412.1105; found: 412.1118.

Compound 16

Compound **15** (0.09 g, 0.22 mmol) was converted to compound **16** (0.05 g, 62%) following the general procedure of ester hydrolysis. White solid. M.P.: > 200 °C. ^1H NMR (600 MHz, $\text{DMSO}-d_6$): δ 3.59-3.62 (m, 1H), 3.69-3.72 (m, 1H), 4.29-4.32 (m, 1H), 4.73 (t, $J = 4.2$ Hz, 1H), 5.63 (d, $J = 7.8$ Hz, 1H), 5.79-5.81 (m, 1H), 6.34 (d, $J = 4.8$ Hz, 1H), 7.78 (d, $J = 8.4$ Hz, 1H), 11.33 (s, 1H). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ 61.0 (CH_2), 66.2, 75.0, 82.5, 85.7, 100.7, 133.4, 140.8, 142.8, 150.9, 159.7, 161.6, 163.8. HRMS (ESI^+): m/z calcd for $\text{C}_{13}\text{H}_{14}\text{N}_5\text{O}_9(\text{M}+\text{H})^+$: 384.0792; found: 384.0786.


Compound 18

Compound **17** (0.32 g, 1.09 mmol) was converted to compound **18** (0.49 g, 77%) following the general procedure of triazolylolation, using 3.0 equivalents of DMAD. [Eluent: 70-75% EtOAc in pet ether]. Yellow gum. ^1H NMR (200 MHz, CDCl_3): δ 1.87 (s, 3H), 2.93-3.03 (m, 2H), 3.85 (s, 3H), 3.91 (s, 3H), 3.94 (s, 3H), 4.02 (s, 3H), 4.89-4.97 (m, 2H), 5.09-5.20 (m, 1H), 5.63-5.74 (m, 1H), 6.13 (m, 1H), 6.90 (s, 1H), 9.46 (s, 1H). ^{13}C NMR (50 MHz, CDCl_3): δ 12.3, 36.7 (CH_2), 50.0 (CH_2), 52.8, 52.9, 53.6, 54.2, 60.1, 81.8, 88.7, 111.6, 131.0, 131.7, 137.6,


139.8, 140.1, 150.2, 158.8, 159.0, 160.2, 160.3, 163.9. HRMS (ESI⁺): m/z calcd for C₂₂H₂₅N₈O₁₁(M+H)⁺ : 577.1643; found: 577.1652.

Compound 19


Compound 19 (61%) was obtained from compound 18 (0.25 g, 0.43 mmol) following the general procedure of ester hydrolysis. White solid. M.P: 196-198 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 1.83 (s, 3H), 2.76-2.80 (m, 2H), 4.76-4.78 (m, 1H), 5.15-5.18 (m, 1H), 5.25-5.31 (m, 1H), 6.31 (bs, 2H), 6.45 (t, *J* = 6.8 Hz, 1H), 7.61 (s, 1H), 11.35 (s, 1H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 12.1, 36.1 (CH₂), 51.7 (CH₂), 60.5, 82.1, 85.1, 110.0, 132.5, 132.6, 136.3, 140.3, 140.7, 150.4, 159.2, 161.3, 161.4, 163.7 (2xC). HRMS (ESI⁺): m/z calcd for C₁₈H₁₆N₈O₁₁Na(M+Na)⁺ : 543.0836; found: 543.0765.




¹H NMR of compound 4




¹H NMR of compound 6




¹³C NMR of compound 6




DEPT 135 NMR of compound 6




¹H NMR of compound 7




¹H NMR of compound 8




^{13}C NMR of compound **8**




DEPT 135 NMR of compound **8**




¹H NMR of compound 10




¹³C NMR of compound 10




DEPT 135 NMR of compound **10**




¹H NMR of compound **11**




¹³C NMR of compound 11




DEPT 135 NMR of compound 11




¹H NMR of compound 12




¹³C NMR of compound 12




DEPT 135 NMR of compound 12




¹H NMR of compound 14




^{13}C NMR of compound 14




DEPT 135 NMR of compound 14




¹H NMR of compound 15




¹³C NMR of compound 15




DEPT 135 NMR of compound **15**




¹H NMR of compound **16**




^{13}C NMR of compound **16**




DEPT 135 NMR of compound **16**




¹H NMR of compound 18




¹³C NMR of compound 18




DEPT 135 NMR of compound **18**



¹H NMR of compound **19**



^{13}C NMR of compound **19**



DEPT 135 NMR of compound **19**




Figure S1: Mechanism for the transphosphorylation and hydrolysis reactions catalyzed by enzyme RNase A.




Figure S2: Transition state during transphosphorylation of UpA by RNase A




Figure S3: Reported nucleoside based Ribonuclease A inhibitors

Reference:

Sulfonic nucleic acids (SNAs): a new class of substrate mimics for ribonuclease A inhibition

Dhrubajyoti Datta, Swagata Dasgupta, Tanmaya Pathak

Org. Biomol. Chem. **2019**, *30*, 7215-7221 (doi: 10.1039/c9ob01250h)




Figure S4: Lineweaver-Burk plot for inhibition of RNase A by (A) **4** of 0.075 (▲), 0.025 (■), 0 (●) mM. (B) **8** of 0.06 (▲), 0.02 (■), 0 (●) mM. (C) **16** of 0.05 (▲), 0.02 (■), 0 (●) mM. (D) **12** of 0.03 (▲), 0.01 (■), 0 (●) mM. 2',3'-cCMP concentrations of 0.89-0.45 mM and RNase A concentration of 9.8-10.1 μ M.




Figure S5: Docked poses of (A) 4 (cyan), (B) 8 (green), (C) 12 (light blue), (D) 19 (magenta), and (E) 16 (dark blue) with RNase A (1FS3)

Table S1: Distances of polar contacts between inhibitors and amino acid residues of RNase A (1FS3)

1FS3	4	8	12	19	16
Arg39 NH1	2.71 Å [O of C2 C=O of nucleobase]		2.45 Å [O of C2 C=O of nucleobase]		
Arg39 NH2	2.94 Å [5' OH]	2.5 Å [O of C2 C=O of nucleobase]	3.2 Å [O of C2 C=O of nucleobase] 2.7 Å [2' OH]		
His119 Nδ1	2.0 Å [OH of acid of C5 of triazole ring]	2.0 Å [OH of acid of C4 of triazole ring]	1.7 Å [OH of acid of C5 of triazole ring]	1.86 Å [C=O of acid of C5 of 3'- triazole ring]	2.03 Å [OH of acid of C5 of triazole ring]
His12 Nε2	2.9 Å [C=O of acid of C5 of triazole ring]	2.9 Å [C=O of acid of C4 of triazole ring]	3.0 Å [C=O of acid of C4 of triazole ring] 2.58 Å [C=O of acid of C5 of triazole ring]	3.0 Å [C=O of acid of C5 of 3'-triazole ring]	2.9 Å [C=O of acid of C5 of triazole ring]
Cys26 CA	3.2 Å [N2 of triazole ring] 3.3 Å [N3 of triazole ring]				
Gln11 Nε2	2.6 Å [N3 of triazole ring]	2.6 Å [C=O of acid of C5 of triazole ring]		3.4 Å [C=O of acid of C4 of triazole ring] 2.75 Å [C=O of acid of C5 of 3'- triazole ring]	2.9 Å [C=O of acid of C5 of triazole ring]
Gln11 CD		2.0 Å [OH of acid of C5 of triazole ring]			
Phe120 N		1.9 Å [OH of acid of C5 of triazole ring]	3.0 Å [C=O of acid of C4 of triazole ring]	2.65 Å [OH of acid of C4 of 3'-triazole ring]	2.76 Å [OH of acid of C5 of triazole ring]
Lys41 Nζ		2.9 Å [C=O of acid of C4 of triazole ring]			
Thr45 CA		2.9 Å [O of C4 C=O of nucleobase]			
Lys7 Nζ			3.0 Å [3' OH] 2.2 Å [N2 of triazole ring] 2.4 Å [N3 of triazole ring]	3.0 Å [O of C2 C=O of nucleobase] 2.74 Å [C=O of acid of C5 of 3'- triazole ring]	2.9 Å [C=O of acid of C4 of triazole ring]
Val118 O				1.96 Å [OH of acid of C5 of 3'-triazole ring] 2.0 Å [OH of acid of C5 of 5'-triazole ring]	2.12 Å [OH of acid of C4 of triazole ring]
Gln69 Nε2				3.2 Å [N3 of 5'- triazole ring]	
Gln69 Oε1				2.35 Å [OH of acid of C5 of 5'-triazole ring]	
Cys 58					2.9 Å [C=O of acid of C4 of triazole ring]
Val 43 O					OH of 5'-CH ₂ OH